• PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

    المصدر: Nasdaq GlobeNewswire / 28 فبراير 2023 16:05:01   America/New_York

    PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March.

    Cowen’s 43rd Annual Health Care Conference (March 6-8, 2023)
    Format:
    Tumor Diagnostic Development Corporate Panel
    Date:Wednesday, March 8, 2023
    Time:9:10 – 10:20 AM ET
      
    Oppenheimer’s 33rd Annual Healthcare Conference (March 13-15, 2023)
    Format:
    Fireside Chat
    Date:Monday, March 13, 2023
    Time:8 AM ET
      

    About PMV Pharma

    PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.

    Contacts

    Investor Contact:
    Winston Kung
    PMV Pharmaceuticals, Inc.
    investors@pmvpharma.com

    Media Contact:
    Kathy Vincent
    Greig Communications
    kathy@greigcommunications.com


    Primary Logo

شارك على،